The CRISPR‐Cas13a Gene‐Editing System Induces Collateral Cleavage of RNA in Glioma Cells

Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage

(2019) Alexander J. Meeske et al.   NATURE

A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment

(2018) Xiao Zhao et al.   CANCER LETTERS

Implementation of the CRISPR-Cas13a system in fission yeast and its repurposing for precise RNA editing

(2018) Xinyun Jing et al.   NUCLEIC ACIDS RESEARCH

RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems

(2018) Alexander J. Meeske et al.   MOLECULAR CELL

RNA targeting with CRISPR–Cas13

(2017) Omar O. Abudayyeh et al.   NATURE

Nucleic acid detection with CRISPR-Cas13a/C2c2

(2017) Jonathan S. Gootenberg et al.   SCIENCE

Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection

(2016) Alexandra East-Seletsky et al.   NATURE

C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector

(2016) Omar O. Abudayyeh et al.   SCIENCE

RNA-based drugs and vaccines

(2014) Kenneth Lundstrom   Expert Review of Vaccines

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

(2013) Yanfang Fu et al.   NATURE BIOTECHNOLOGY

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL